Comparison of a new endoprosthesis to traditional stenting for iliac artery disease
Official title: The GORE VBX FORWARD Clinical Study: A Comparison of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis to Bare Metal Stenting for Patients With Complex Iliac Occlusive Disease
Run by W.L.Gore & Associates · NCT05811364 · Data updated 2026-11-12
This study is testing a new type of stent for people with iliac artery disease to see if it works better than the traditional metal stents in improving blood flow and relieving symptoms.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 244 (estimated) |
| Sponsor | W.L.Gore & Associates Industry-sponsored |
| Locations | 43 sites (Little Rock, Arkansas and 42 other locations) |
| Status | Recruiting |
| Started | October 17, 2023 |
| Main results expected | March 30, 2028 |
| Study ends | January 31, 2032 |
| Registry record updated | May 13, 2026 |
| Trial ID | NCT05811364 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 and older with symptomatic claudication or related conditions and specific lesions in their iliac arteries.
✕Probably not a fit
Patients with a life expectancy of less than one year or those who are pregnant will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial aims to compare the effectiveness of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis against traditional bare metal stenting in patients suffering from complex iliac occlusive disease. It is a multicenter, randomized, controlled trial designed to demonstrate the superiority of the VBX device in achieving primary patency. Eligible participants will include those with symptomatic claudication or other related conditions and specific lesion characteristics in their iliac arteries. The study will assess outcomes related to blood flow restoration and symptom relief.
Why it matters
Potential benefit: If successful, this study could provide a more effective treatment option for patients with complex iliac occlusive disease, potentially improving their quality of life.
How similar studies have gone: Other studies have shown promising results with similar endoprosthesis approaches, indicating potential for success in this trial.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years at time of informed consent signature * Informed Consent Form (ICF) is signed by the subject * Subject can comply with protocol requirements, including follow-up * Patient has symptomatic claudication, rest pain, or minor tissue loss (Rutherford Category 2-5) * Patient has de novo or restenotic lesion(s) found in the common and/or external iliac artery(ies) * Patient has: Unilateral or bilateral single or multiple lesions (\>50% stenosis or chronic total occlusion) each between 4 and 11 cm in length * Patient has a target vessel diameter visually estimated to be approximately between 5 mm and 13 mm * Patient has a sufficient (\<50% stenotic) common femoral artery and at least one sufficient (\<50% stenotic) femoral artery (deep or superficial). * Patient has at least one sufficient (\<50% stenotic) infrapopliteal run-off vessel. Exclusion Criteria: * Life expectancy \<1 year * Patient is pregnant at time of informed consent. * Patient has a known allergy to stent or stent graft components (including nitinol, stainless steel, or heparin). * Patient has severe chronic renal insufficiency (serum creatinine level \> 2.5mg/dL) and not undergoing hemodialysis. * Patient has evidence of a systemic infection. * Patient has a known intolerance to antithrombotic medications that prevent compliance with study or control device Instructions for Use. * Patient has had vascular catheterization of the lower extremities within 30 days of randomization (excluding diagnostic angiograms for the study procedure). * Patient has previous stenting in the iliac arteries. * Patient has previous surgical bypass in the target limb. * Patient is currently participating in another investigative clinical study unless received written approval by the sponsor. * Patient has a lesion requiring drug-coated balloon angioplasty, atherectomy, lithotripsy, or any ablative device to facilitate stent delivery. * Patient has an abdominal aortic artery lesion or aneurysm. * Patient has a lesion that requires stent placement within 2 cm of the inguinal ligament. * Patient has isolated common iliac artery stenosis that can be treated with a single device (i.e., common iliac artery stenosis that does not require kissing stents or extend into the external iliac artery). * Patient has outflow disease that requires concomitant interventions (i.e. common femoral endarterectomy or femoral / tibial revascularization).
Where it's running
-
VA Long Beach Healthcare System
Long Beach, California, United States Recruiting -
Denver Health and Hospital Authority
Denver, Colorado, United States Recruiting -
University of Florida - Gainesville
Gainesville, Florida, United States Recruiting -
Radiology and Imaging Specialists of Lakeland
Lakeland, Florida, United States Recruiting -
University of South Florida
Tampa, Florida, United States Recruiting -
Atlanta VA Medical Center
Decatur, Georgia, United States Recruiting
Show 37 more locations
-
Louisiana State University Health Sciences Center
New Orleans, Louisiana, United States Recruiting -
Beth Israel Deaconess Medical Center, Inc.
Boston, Massachusetts, United States Recruiting -
Corewell Health System
Grand Rapids, Michigan, United States Recruiting -
The Curators of the University of Missouri
Columbia, Missouri, United States Recruiting -
Trinity Medical Center
Buffalo, New York, United States Recruiting -
VA Western New York Healthcare System
Buffalo, New York, United States Recruiting -
New York University School of Medicine
New York, New York, United States Recruiting -
Mt. Sinai Medical Center
New York, New York, United States Recruiting -
Atrium Health
Charlotte, North Carolina, United States Recruiting -
University Hospitals - Cleveland Medical Center
Ashland, Ohio, United States Recruiting -
Cleveland Clinic Foundation
Cleveland, Ohio, United States Recruiting -
Portland Health Care System VA
Portland, Oregon, United States Recruiting -
Providence Heart & Vascular Institute
Wilsonville, Oregon, United States Recruiting -
University of Pennsylvania
Philadelphia, Pennsylvania, United States Recruiting -
Wellmont Holston Valley Medical Center
Kingsport, Tennessee, United States Recruiting -
The University of Texas Southwestern Medical Center
Dallas, Texas, United States Recruiting -
Sentara Medical Group
Norfolk, Virginia, United States Recruiting -
Central Adelaide Local Health Network Incorporated
Adelaide, Australia Recruiting -
Royal Perth Hospital
Nedlands, Australia Recruiting -
Prince of Wales Hospital
Randwick, Australia Recruiting -
Universitats-Herzzentrum Freiburg Bad Krozingen GmbH
Bad Krozingen, Germany Recruiting -
St. Franziskus Hospital
Münster, Germany Recruiting -
Krankenhaus der Barmherzigen Brüder
Regensburg, Germany Recruiting -
Klinikum Stuttgart
Stuttgart, Germany Recruiting -
Ospedale Niguarda Ca'Granda
Milan, Mi, Italy Recruiting -
Ospedale Santa Maria della Misericordia
Perugia, Italy Recruiting -
Azienda Complesso Ospedaliero San Filippo Neri
Roma, Italy Recruiting -
Ospedale San Giovanni Molinette
Turin, Italy Recruiting -
Rijnstate Hospital
Arnhem, Netherlands Recruiting -
Stichting Elisabeth-TweeSteden Ziekenhuis
Tilburg, Netherlands Recruiting -
Auckland City Hospital
Auckland, New Zealand Recruiting -
East Kent Hospitals University NHS Foundation Trust
Canterbury, United Kingdom Recruiting -
Guy's and St Thomas', NHS Foundation Trust
London, United Kingdom Recruiting -
University Hospital Southampton NHS Foundation Trust
Southampton, United Kingdom Recruiting -
Central Arkansas Veterans Healthcare System
Little Rock, Arkansas, United States Withdrawn -
North Suburban Medical Center
Denver, Colorado, United States Withdrawn -
Research Foundation SUNY Buffalo
Amherst, New York, United States Withdrawn
Study contacts
- Study coordinator: Alexander Ambrocik
- Email: aambroc@wlgore.com
- Phone: 337-387-4954
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Predictors of Major Adverse Limb Events After Iliac Artery Stenting
This study tests what factors predict serious limb-related problems after iliac artery stenting in adults with peripheral artery disease.
-
Preventing lower limb artery disease in adults with diabetes using a risk-prediction model and HAPA-based nursing
A risk-prediction model is tested in adults with type 2 diabetes to see if a nursing plan based on the HAPA model can reduce peripheral artery disease in the legs.
-
New prodrug CG-0255 Besylate vs Plavix in healthy adults
This study tests whether CG-0255 Besylate works similarly to Plavix® in healthy adults to understand how the two drugs behave in the body.
-
Radial and Ulnar Access in Vascular Interventions Registry
This registry tests how often radial or ulnar artery access is used and what happens afterward in routine vascular procedures.
-
Remote versus in-person 30-second sit-to-stand testing for people with peripheral artery disease
This project will test whether doing the 30-second sit-to-stand test by video works as well as doing it in person for adults aged 18–65 with Fontaine stage I–II peripheral artery disease who have a smartphone.
-
Imaging plaque activity across the body in people with symptomatic peripheral arterial disease
This project will use whole-body PET-CT and CT angiography with several tracers to see if imaging can detect inflammation, microcalcification, and clot activity in people with symptomatic peripheral arterial disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.